0
Correspondence |

Kinetics and Specificity of Fas Ligand Induction in Toxic Epidermal Necrolysis

Howard Y. Chang, MD, PhD; Zachary A. Cooper, MD; Susan M. Swetter, MD; M. Peter Marinkovich, MD
Arch Dermatol. 2004;140(2):242-244. doi:10.1001/archderm.140.2.242.
Text Size: A A A
Published online

Extract

Toxic epidermal necrolysis (TEN) is a severe drug-induced bullous eruption that has significant mortality and morbidity.1 Induction of Fas ligand, a cytokine that induces apoptosis, may mediate cell death in TEN in part because the soluble Fas ligand (sFasL) level is elevated in the blood of patients with TEN.2 Pooled human immunoglobulin blocks the action of Fas and may be beneficial in TEN.2 The kinetics and specificity of sFasL induction in TEN and other bullous dermatoses are unknown. We present preliminary results of serial sFasL measurement in a patient with TEN and 10 patients with 5 types of chronic bullous diseases.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure 1.

Clinical and histologic findings of a patient with toxic epidermal necrolysis. A, Erosion on the lips and hard palate and scattered bullae with erythematous macules were noted on the first day of the skin eruption. B and C, The erythematous macules on the trunk and soles progressed to tense bullae by day 2. By day 7 oral lesions had healed (D) and most of the bullae were covered by hemorrhagic crust and had begun reepithelialization (E). F, Skin with subepidermal split (arrow) and an overlying area of confluent epidermal necrosis (arrowhead) (hematoxylin-eosin, original magnification ×100). The dermis shows only a sparse lymphohistiocytic infiltrate.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Serologic studies of soluble Fas ligand (sFasL). A, Kinetics of sFasL in toxic epidermal necrolysis. Concentration of sFasL is shown on the left axis and the extent of total body surface area (TBSA) involved by toxic epidermal necrolysis is estimated on the right axis. sFasL was measured in triplicate, and the mean values are shown. The SD ranges from 15.2% to 20% of the mean value. Arrowheads signify the times when immunoglobulin (IVIG) was infused. The upper limit of normal level of sFasL (0.1 ng/mL) is shown by the dashed line. B, Specificity of sFasL in autoimmune bullous diseases. Shown are serum levels of sFasL in a normal donor; patients with bullous pemphigoid (BP); subepidermal, lamina lucida blistering disease (Chan disease)4; cicatricial pemphigoid (CP); epidermolysis bullosa acquisita (EBA); linear IgA bullous dermatosis (LABD); and pemphigus vulgaris (PV). Dashed line denotes upper limit of normal level of sFasL.

Graphic Jump Location

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
brightcove.createExperiences();